SUZETRIGINE - Generic Drug Details

What are the generic drug sources for suzetrigine and what is the scope of freedom to operate?

Suzetrigine is the generic ingredient in one branded drug marketed by Vertex Pharms Inc and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Suzetrigine has forty patent family members in thirty-five countries.

One supplier is listed for this compound.

Summary for SUZETRIGINE

International Patents:	40
US Patents:	1
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	18
Patent Applications:	15
What excipients (inactive ingredients) are in SUZETRIGINE?	SUZETRIGINE excipients list
DailyMed Link:	SUZETRIGINE at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for SUZETRIGINE

Constraining patent/regulatory exclusivity:

NEW CHEMICAL ENTITY

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for SUZETRIGINE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
AdventHealth	PHASE3
Mayo Clinic	PHASE4
American Association of Hip and Knee Surgeons	PHASE3

See all SUZETRIGINE clinical trials

Pharmacology for SUZETRIGINE

Drug Class	Sodium Channel Blocker
Mechanism of Action	Cytochrome P450 3A Inducers Sodium Channel Antagonists

US Patents and Regulatory Information for SUZETRIGINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Vertex Pharms Inc	JOURNAVX	suzetrigine	TABLET;ORAL	219209-001	Jan 30, 2025		RX	Yes	Yes			Y	Y
Vertex Pharms Inc	JOURNAVX	suzetrigine	TABLET;ORAL	219209-001	Jan 30, 2025		RX	Yes	Yes

International Patents for SUZETRIGINE

Country	Patent Number	Title	Estimated Expiration
Ecuador	SP22052564
Chile	2022001489
Lithuania	4069691
Slovenia	4069691
World Intellectual Property Organization (WIPO)	2021113627
South Korea	20220124176

Last updated: May 22, 2026

Suzetrigine (SUZETRIGINE) market dynamics and financial trajectory: exclusivity, competition, and revenue risk

What market dynamics shape Suzetrigine (SUZETRIGINE) demand and pricing?

No response.

How strong is the Suzetrigine patent estate for blocking generics and biosimilars?

No response.

When does Suzetrigine lose exclusivity under FDA Orange Book listings and pediatric/market exclusivity?

No response.

How many Paragraph IV challenges target Suzetrigine and what settlements changed the launch calendar?

No response.

What is the FDA regulatory pathway status of Suzetrigine (NDA, 505(b)(2), ANDA, or 505(j))?

No response.

What formulations and method-of-use patents protect Suzetrigine and what does that mean for line extensions?

No response.

Which companies compete with Suzetrigine and how does the competitive landscape affect market share?

No response.

What are Suzetrigine revenue drivers and gross-to-net dynamics (pricing, rebates, channel mix)?

No response.

What is the financial trajectory for Suzetrigine (launch year through maturity) and what metrics matter most?

No response.

How does Suzetrigine compare with treated alternatives in sales, utilization, and payer strategy?

No response.

What generic entry risks exist for Suzetrigine by dosing form, strength, and geography?

No response.

What manufacturing/IP barriers could delay or constrain generic supply for Suzetrigine?

No response.

Key Takeaways

No response.

FAQs

No response.

References (APA)

No response.